Aleix Prat: Excited to unveil our lab’s TOP-11 2023 research articles in breast cancer
Aleix Prat, Director of Cancer Institute at Hospital Clinic of Barcelona, shared on LinkedIn:
“Excited to unveil our lab’s TOP-11 2023 research articles in breast cancer.
Check out the thread below for the highlights!
A big thank you to our collaborators worldwide!
Num1
Tolaney et al., Lancet Oncol APT 10-year and HER2DX
HER2DX risk score was significantly associated with invasive disease-free survival (hazard ratio [HR] per 10-unit increment 1·24 [95% CI 1·00–1·52]; p=0·047) and recurrence-free interval (1·45 [1·09–1·93]; p=0·011)
Read the article in The Lancet.
Num2
Waks et al., JAMA Oncol HER2DX in DAPHNe
The HER2DX pCR score was significantly associated with pCR (odds ratio, 1.05; P < .001).
The pCR rates in the HER2DX high, medium, and low pCR score groups were 92.6%, 63.6%, and 29.0%, respectively (high vs low odds ratio, 30.6; P < .001).’
Read the article in JAMA Oncology.
Num3
Bueno-Muiño et al., JAMA Oncol HER2DX in GOM
The assay-reported pCR score (as a continuous variable from 0-100) showed a statistically significant association with pCR (odds ratio [OR] per 10-unit increase, 1.43; P < .001).
The pCR rates in the assay-reported pCR-high and pCR-low groups were 75.0% and 28.3%, respectively (OR, 7.85; 95% CI, 2.67-24.91; P < .001).
A statistically significant interaction between the assay-reported pCR score and the effect of pertuzumab in pCR was observed.
Read the article in JAMA Oncology.
Num4
Prat et al., Nature Communications — New applications for ctDNA
We demonstrate that machine learning multi-gene signatures, obtained from ctDNA, identify complex biological features, including measures of tumor proliferation and estrogen receptor signaling, similar to what is accomplished using direct tumor tissue DNA or RNA profiling.
Read the article in Nature.
Num5
Prat et al., Clinical Cancer Res — Subtype in MBC HR+/HER2-
The luminal A subtype had the best OS outcomes in both arms, while basal-like had the worst. Patients with HER2E (HR, 0.60; P=.018), luminal B (HR, 0.69; P=.023), and luminal A (HR, 0.75; P=.021) subtypes derived OS benefit with ribociclib. Patients with basal-like subtype did not derive benefit from ribociclib (HR, 1.92; P=.137)
Num6
Brasó-Maristany et al. JNCI — HER2DX vs TDM1
Num7
Dieci et al. JNCI — Patterns of relapse in HER2+
Num8
Villacampa et al. European J Cancer — Treatments in HER2+
Num9
Fernandez et al. JAMA Oncology — TILs vs B-cell signatures in HER2+
Num10
Weiss et al. Cancer — Nodal positivity in HER2+
Num11
Villacampa et al. Annals of Oncology — HER2DX pCR score meta-analysis
Visit the article website.”
Source: Aleix Prat/LinkedIn